SCHEMBL3068209

SCHEMBL3068209

CN(C)C1CCN(C(=O)Cl)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.45
CDYL Q9Y232 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM1A O60341 2/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
HDAC4 P56524 1/20 0.36
ALDH1A1 P00352 2/20 0.35
PARP1 P09874 2/20 0.34
MCHR1 Q99705 1/20 0.34
MALT1 Q9UDY8 1/20 0.34
BDKRB1 P46663 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27781047 0.82 L3MBTL3 (0.60) L3MBTL3L3MBTL1CDYLCDY1; CDY1BKDM1A
SCHEMBL26683504 0.82 L3MBTL3 (0.40) L3MBTL3L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL3104303 0.80 L3MBTL3 (0.58) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1
SCHEMBL4550247 0.80 L3MBTL3 (0.58) L3MBTL3L3MBTL1SMN1; SMN2
SCHEMBL8679035 0.79 L3MBTL3 (0.53) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1
SCHEMBL2232096 0.79 L3MBTL3 (0.38) L3MBTL3L3MBTL1ALDH1A1
SCHEMBL8362221 0.78 L3MBTL3 (0.56) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1
SCHEMBL22878132 0.78 L3MBTL3 (0.56) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1
SCHEMBL20842232 0.78 L3MBTL3 (0.56) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1
SCHEMBL425964 0.78 L3MBTL3 (0.56) L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567041-B1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2023-12-27 EP disclosed
CN-110167941-B Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof 上海瑛派药业有限公司 2023-04-04 CN disclosed
EP-3567041-A9 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-04-20 EP disclosed
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2020-12-29 US disclosed
EP-3567041-A1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics, Inc (CN) 2019-11-13 EP disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed
EP-1022277-B1 NEW TAXANE DERIVATIVES YAKULT HONSHA KK (JP) 2002-12-04 EP disclosed
US-6268381-B1 Taxane derivatives KABUSHIKI KAISHA YAKULT HONSHA (JP) 2001-07-31 US disclosed
US-6136808-A ANTITUMOR AGENTS FROM PLANTS KABUSHIKI KAISHA YAKULT HONSHA (JP) 2000-10-24 US disclosed
EP-1044971-A1 TAXANE DERIVATIVES Kabushiki Kaisha Yakult Honsha (JP) 2000-10-18 EP disclosed
EP-1022277-A1 NEW TAXANE DERIVATIVES Kabushiki Kaisha Yakult Honsha (JP) 2000-07-26 EP disclosed
US-6025385-A HIGH SOLUBILITY IN WATER AND ALSO HAS EXCELLENT ANTITUMOR ACTIVITIES. KABUSHIKI KAISHA YAKULT HONSHA (JP) 2000-02-15 US disclosed
EP-0930309-A1 TAXANE DERIVATIVES AND DRUGS CONTAINING THE SAME KABUSHIKI KAISHA YAKULT HONSHA (JP) 1999-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 L3MBTL3 901/4885L3MBTL1 791/4885CDYL 4061/4885
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof CHEK1, CHEK2, CDK1 L3MBTL3 788/4885L3MBTL1 712/4885CDYL 2719/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 L3MBTL3 901/4885L3MBTL1 791/4885CDYL 4061/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 L3MBTL3 901/4885L3MBTL1 791/4885CDYL 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.